{"id":963515,"date":"2026-05-15T10:20:22","date_gmt":"2026-05-15T14:20:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/"},"modified":"2026-05-15T10:20:22","modified_gmt":"2026-05-15T14:20:22","slug":"alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/","title":{"rendered":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award<\/b><\/p>\n<p>MOUNTAIN VIEW, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&amp;S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&amp;S alumni who are making transformational contributions to biomedical research within 25 years of graduation.<\/p>\n<p>\n\u201cHaving led global neuroscience R&amp;D efforts for many years, I recognize that true transformation requires moving beyond the &#8216;one-size-fits-all&#8217; model,\u201d said Husseini Manji, M.D., member of the Alto Neuroscience Board of Directors and former Global Head of Neuroscience at Johnson &amp; Johnson. \u201cAmit\u2019s work, honored today by Columbia, represents the successful bridging of elite academic inquiry and industrial-scale innovation. He has moved the needle from theoretical biomarkers to a clinical-stage pipeline that has the potential to redefine how we treat mental health in a markedly improved manner.\u201d<\/p>\n<p>\nDr. Etkin earned his MD and PhD with distinction from Columbia University under Nobel laureate Dr. Eric Kandel, joined the Stanford faculty in 2010, and received the NIH Director\u2019s Pioneer Award \u2014 the most competitive NIH grant and the first ever awarded in clinical psychiatry. He founded Alto in 2019, where he leads development of the Precision Psychiatry Platform\u2122, which uses brain-based biomarkers to identify patients most likely to respond to specific treatments. Alto\u2019s clinical-stage pipeline programs span major depressive disorder, bipolar depression, treatment-resistant depression, and schizophrenia, with multiple mid- to late-stage data readouts expected across the coming two years.<\/p>\n<p>\n\u201cI am deeply honored to receive this award from Columbia,\u201d said Dr. Etkin. \u201cMy years at Columbia \u2014 learning from some of the most brilliant scientific minds in the world, including Dr. Kandel \u2014 shaped my conviction that understanding the brain at a fundamental level is the key to transforming how we treat psychiatric disease. That conviction truly motivates our work at Alto, and I dedicate this recognition to the patients we serve and the remarkable team at Alto working to bring better treatments to them.\u201d<\/p>\n<p>\nFor more information about the award, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vagelos.columbia.edu%2Fnews%2Famit-etkin-06-winner-transformational-research-award&amp;esheet=54536571&amp;newsitemid=20260515727151&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.vagelos.columbia.edu%2Fnews%2Famit-etkin-06-winner-transformational-research-award&amp;index=1&amp;md5=102a5991044b74bbf2a3ab273dcd2105\">https:\/\/www.vagelos.columbia.edu\/news\/amit-etkin-06-winner-transformational-research-award<\/a>.<\/p>\n<p><b>About Alto Neuroscience<\/b><\/p>\n<p>\nAlto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto\u2019s Precision Psychiatry Platform\u2122 measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto\u2019s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, schizophrenia, and other mental health conditions. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.altoneuroscience.com%2F&amp;esheet=54536571&amp;newsitemid=20260515727151&amp;lan=en-US&amp;anchor=www.altoneuroscience.com&amp;index=2&amp;md5=800e996cf81e39bc8838dc15598434e8\">www.altoneuroscience.com<\/a> or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FAltoNeuro&amp;esheet=54536571&amp;newsitemid=20260515727151&amp;lan=en-US&amp;anchor=follow+Alto+on+X&amp;index=3&amp;md5=e7c18147f05fe6f61838d7b3fbca3f23\">follow Alto on X<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201canticipates,\u201d \u201cexpects,\u201d \u201cmay,\u201d \u201cwill,\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto\u2019s expectations about the potential benefits, activity, effectiveness, tolerability and safety of its product candidates and Precision Psychiatry Platform (\u201cPlatform\u201d); Alto\u2019s expectations with regard to its research and development programs and clinical trials, including the timing and availability of data from such trials; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the availability and timing of results from clinical trials; and other important factors, any of which could cause Alto\u2019s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled \u201cRisk Factors\u201d in Alto\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (\u201cSEC\u201d) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.<\/p>\n<p><b>Availability of Information on Alto\u2019s Website<\/b><\/p>\n<p>\nAlto routinely uses its investor relations <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.altoneuroscience.com%2Foverview%2Fdefault.aspx&amp;esheet=54536571&amp;newsitemid=20260515727151&amp;lan=en-US&amp;anchor=website&amp;index=4&amp;md5=377452f2e818675b6c31cac6a3f6a086\">website<\/a> to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260515727151\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260515727151\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Nick Smith<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@altoneuroscience.com\">investors@altoneuroscience.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:media@altoneuroscience.com\">media@altoneuroscience.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Health General Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260515727151\/en\/1266385\/3\/Alto_Neuroscience.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&amp;S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&amp;S alumni who are making transformational contributions to biomedical research within 25 years of graduation. \u201cHaving led global neuroscience R&amp;D efforts for many years, I recognize that true transformation requires moving beyond the &#8216;one-size-fits-all&#8217; model,\u201d said Husseini Manji, M.D., member of the Alto Neuroscience Board of Directors and former Global Head &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963515","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&amp;S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&amp;S alumni who are making transformational contributions to biomedical research within 25 years of graduation. \u201cHaving led global neuroscience R&amp;D efforts for many years, I recognize that true transformation requires moving beyond the &#8216;one-size-fits-all&#8217; model,\u201d said Husseini Manji, M.D., member of the Alto Neuroscience Board of Directors and former Global Head &hellip; Continue reading &quot;Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T14:20:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award\",\"datePublished\":\"2026-05-15T14:20:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/\"},\"wordCount\":864,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/\",\"name\":\"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-15T14:20:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/","og_locale":"en_US","og_type":"article","og_title":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk","og_description":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&amp;S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&amp;S alumni who are making transformational contributions to biomedical research within 25 years of graduation. \u201cHaving led global neuroscience R&amp;D efforts for many years, I recognize that true transformation requires moving beyond the &#8216;one-size-fits-all&#8217; model,\u201d said Husseini Manji, M.D., member of the Alto Neuroscience Board of Directors and former Global Head &hellip; Continue reading \"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T14:20:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award","datePublished":"2026-05-15T14:20:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/"},"wordCount":864,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/","name":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-15T14:20:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260515727151r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-ceo-amit-etkin-m-d-ph-d-receives-columbia-university-transformational-research-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963515"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963515\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}